ITRMF.US Iterum Therapeutics plc
- Market cap
- USD 532.00
- P/E
- -
- P/B
- 0.43x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2025.
Is ITRMF.US undervalued?
Graham numberThe Graham number of Iterum Therapeutics plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Iterum Therapeutics plc fundamental analysis
No fundamental analysis for Iterum Therapeutics plc yet.
Iterum Therapeutics plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Iterum Therapeutics plc
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developi…
Full company profileIterum Therapeutics plc financial statements
2025 annualized: Fiscal year 2025 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2025, the balance sheet is the latest quarter. Figures change when the annual report is published.
Iterum Therapeutics plc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 520K |
| Gross Profit | - | 0.00 | 0.00 | -254K | -423K |
| Operating Income | -24.5M | -30.4M | -47.5M | -18.7M | -22.6M |
| EBITDA | -83.2M | -40.0M | -34.6M | -21.7M | -23.7M |
| Net Income | -91.6M | -44.4M | -38.4M | -24.8M | -27.2M |
| EPS | -6.93 | -3.25 | -2.62 | -0.79 | -0.55 |
| Balance Sheet | |||||
| Total Assets | 91.5M | 66.8M | 26.3M | 44.6M | 32.5M |
| Total Liabilities | 41.3M | 38.8M | 32.7M | 48.7M | 39.9M |
| Shareholders' Equity | 50.2M | 28.0M | -6.40M | -4.08M | -7.38M |
| Cash & Short-term Investments | 27.4M | 21.1M | 6.07M | 24.1M | 11.0M |
| Cash Flow | |||||
| Operating Cash Flow | -15.8M | -18.5M | -39.3M | -26.8M | -20.3M |
| Capital Expenditure | 61.0K | 62.0K | 13.0K | 2.00K | 18.7K |
| Free Cash Flow | -15.9M | -18.5M | -39.3M | -26.8M | -20.4M |
| Ratios | |||||
| ROE | -182.3% | -158.7% | - | - | - |
| ROA | -100.1% | -66.5% | -146.1% | -55.6% | -83.6% |
| Net Profit Margin | - | - | - | - | -5,225.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Iterum Therapeutics plc dividends
Iterum Therapeutics plc has not paid dividends in the last 4 fiscal years.
Last stock split: 1:15 on Aug 18, 2022.
Who owns Iterum Therapeutics plc
- Insiders 0.78%
- Institutions 0.52%
- Public & others 98.70%
- Shares outstanding 53.3M
- Free float 52.4M
Iterum Therapeutics plc company profile
- Company name
- Iterum Therapeutics plc
- Ticker
- ITRMF.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 9
- Fiscal year end
- December
- Address
- 3 Dublin Landings, Dublin, Ireland, D01 C4E0
- Phone
- 353 1 903 8354
- Website
- iterumtx.com
About Iterum Therapeutics plc
Iterum Therapeutics plc, a pharmaceutical company, develops and commercializes treatments for drug resistant bacterial infections in Ireland, Bermuda, and the United States. The company offers ORLYNVAH, an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis microorganisms in adult women with limited or no alternative oral antibacterial treatment options. It is also developing sulopenem, a novel anti-infective compound with oral and intravenous formulations to treat uncomplicated urinatry tract infections, complicated urinary tract infections, and complicated intra-abdominal infections, as well as community-acquired bacterial pneumonia, acute bacterial prostatitis, gonococcal urethritis, and pelvic inflammatory diseases. Iterum Therapeutics plc was incorporated in 2015 and is headquartered in Dublin, Ireland. Iterum Therapeutics plc is in reorganization.
Iterum Therapeutics plc management
5- Dr. Michael W. Dunne M.D.Strategic Advisor & Director · born 1960
- Mr. Tom Loughman Ph.D.Senior Vice President of Technical Operations
- Kevin DaltonSenior Director of Legal Affairs & Company Secretary
- Dr. Steven I. Aronin M.D.Senior VP & Head of Clinical Development
- Ms. Christine R. Coyne M.B.A.Chief Commercial Officer · born 1970